Skip to content

Protagonist Therapeutics PTGX Other Income (Expense)

Other Income (Expense) at other companies

Eli Lilly logo
Eli LillyLLY
-$65M+72.8%
Amgen logo
AmgenAMGN
$75M-95.1%
Incyte logo
IncyteINCY
$2.77M-65.7%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
-$23.36M-366%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$188.3M-39.9%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE

Other financials

Income statement

See full
Revenue$56.4M+99.0%
Operating income-$3.6M+81.1%
Net income$3.8M+132%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$193.7M+38.7%
Total debt$9.8M-13.9%
Total equity$655.5M-4.9%
Total assets$697.5M-6.0%

Cash flow

See full
Operating cash flow-$48.9M-139%
CapEx$215.0K-60.6%
Free cash flow-$49.2M-139%

Valuation

See full
Market cap$7.26B+127%
Enterprise value$7.07B+130%
P/S98×+82.6×

Profitability

See full
Operating margin-192.4%-205pp
Net margin-154.9%-182pp
FCF margin-12,264.3%-12,527pp

Returns & leverage

See full
Return on equity-17.1%-26.1pp
Debt / equity0.0×
Current ratio17.8×+0.5×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Protagonist Therapeutics's other income (expense)?
Protagonist Therapeutics (PTGX) reported other income (expense) of $53K in Q1 2026.
How has Protagonist Therapeutics's other income (expense) changed year-over-year?
Protagonist Therapeutics's other income (expense) decreased by 35.4% year-over-year, from $82K to $53K.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.